Abstract
Transcatheter aortic valve implantation (TAVI) is evolving rapidly as a therapeutic option in patients deemed to be at high risk for surgical aortic valve replacement. Early outcome and survival of controlled feasibility trials and single- center experience with TAVI have been previously reported. Valve performance and hemodynamics seem to improve significantly after TAVI. Long-term outcome up to 3 years have been demonstrated in recent studies. Admittedly, the results are encouraging with a survival rate at 2 and 3 years ranging from 62 to 74% and from 56 to 61% respectively. The improvement in hemodynamical and clinical status sustained beyond the 3 years follows up. However, paravalvular leakage after TAVI remains an important issue in this rapidely evolving field.
Original language | English |
---|---|
Pages (from-to) | 295-298 |
Number of pages | 4 |
Journal | Current Cardiology Reviews |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - 2013 |
Keywords
- Aortic stenosis
- Aortic valve
- Paravalvular leakage
- SAVR
- TAVI